Zydus Lifesciences Draws One Observation at Its Ahmedabad Plant, a Day After a Clean Check Elsewhere

The Zydus Lifesciences USFDA inspection at SEZ II, Ahmedabad, ran from 21 to 28 September 2026 as a current good manufacturing practice check. The inspection closed with one observation, and the company specifically noted there were no data-integrity-related findings.

Click Here – Get Free Investment Predictions

The Zydus Lifesciences USFDA inspection follows a separate check at the company's New Jersey pharmacovigilance office that concluded with nil observations only days earlier. The two inspections cover different functions, a manufacturing plant versus a safety-reporting office, so this article treats the Ahmedabad result on its own terms rather than as a repeat of the earlier news.

Zydus Lifesciences USFDA Inspection: What the SEZ II Check Covered

Item	Detail
Regulator	US Food and Drug Administration
Site	SEZ II manufacturing plant, Ahmedabad
Inspection type	Current good manufacturing practice (cGMP)
Dates	21 to 28 September 2026
Outcome	One observation, no data-integrity issues

The Zydus Lifesciences USFDA inspection at SEZ II is a cGMP check, which examines the physical processes, documentation and quality systems behind drug production, which is a different scope from a pharmacovigilance audit that checks how a company tracks adverse events after a drug is sold. One observation is a single point the inspector wants addressed, not a systemic failure, and the absence of a data-integrity finding is meaningful because those are typically treated as the most serious category.

Also read – NCC Wins a Rs 1,077 Crore Andhra Pradesh Water Order the Same Day the Stock Hits a Fresh 52-Week Low

Zydus Lifesciences Share Price Today: Numbers and Technical Levels

Metric	Value (29 Sep, 10:22 AM)
Zydus Lifesciences share price	Rs 1,215.30 (up 0.02%)
Previous close	Rs 1,215.00
Day range	Rs 1,209.00 to Rs 1,232.10
52-week high / low	Rs 1,232.10 / Rs 835.50
Volume so far	6.14 lakh shares
RSI (14-day)	71.0
MACD vs signal line	17.07 vs 8.18
SuperTrend	Bullish, support at Rs 1,141.36
20-day average	Rs 1,153.05
Market cap (Friday close)	Rs 1,19,900 crore
P/E vs industry P/E	26.11 vs 38.42

The Zydus Lifesciences share price is just 1.4 percent below its 52-week high of Rs 1,232.10 and has risen 45.4 percent from its 52-week low of Rs 835.50. An RSI of 71.0 is above the conventional overbought line of 70, so the stock has run up sharply into this inspection outcome.

The stock behind the Zydus Lifesciences USFDA inspection news is 5.4 percent above its 20-day average of Rs 1,153.05, and the SuperTrend indicator shows a bullish trend with support at Rs 1,141.36. The MACD line remains well above its signal line, confirming strong recent momentum.

Zydus Lifesciences USFDA Inspection: One Observation Versus Nil

The New Jersey pharmacovigilance inspection, covering 22 to 25 September, ended with nil observations at a safety-reporting office. This Ahmedabad inspection, covering a wider window of 21 to 28 September at a manufacturing plant, ended with one observation. Comparing the two directly would overstate what changed, since they tested different systems.

What both parts of the Zydus Lifesciences USFDA inspection record share is the absence of any data-integrity concern, which is the category regulators treat most seriously and which has previously triggered warning letters and Official Action Indicated classifications for the company, including at its Baddi and Jarod facilities.

Compare Pharma Valuations on the Univest Screener

Financial Strength Behind the Zydus Lifesciences Share Price

After the Zydus Lifesciences USFDA inspection outcome, the stock trades at a P/E of 26.11 against an industry figure of 38.42, a discount that leaves room for a re-rating if future inspection outcomes stay clean. Return on equity is 18.59 percent, debt to equity is 0.46, and the company approved a Rs 1,100 crore buyback alongside its Q4 FY26 results.

The dividend yield is low at 0.08 percent, so most of the return case for the Zydus Lifesciences share price rests on earnings growth and multiple re-rating rather than income.

Risks for the Zydus Lifesciences Share Price

An RSI above 70 flags stretched short-term momentum for the stock following the Zydus Lifesciences USFDA inspection, and any negative surprise, including the detail of what this one observation covers once disclosed, could trigger profit-taking after the recent run. Regulatory risk remains structural for the company given its history of more serious findings at other plants.

Broader US pricing pressure on generics and reliance on continued clean inspections across multiple sites are the other risks investors should weigh before treating this specific update as a reason to chase the stock higher.

Download the Univest iOS App or Univest Android App to track the Zydus Lifesciences share price and get alerts on USFDA inspections.

Conclusion

Zydus Lifesciences' SEZ II Ahmedabad plant drew one USFDA observation with no data-integrity issue, a manageable outcome that follows a separate clean pharmacovigilance check at a different site. A P/E of 26.11 against 38.42 for the industry and an 18.59 percent return on equity are supports, while an RSI above 70 shows the Zydus Lifesciences share price has already run up sharply. Investors deciding whether to buy Zydus Lifesciences shares should watch the Rs 1,141.36 support, follow stop-loss levels and consult a SEBI-registered adviser.

Frequently Asked Questions

What is the Zydus Lifesciences share price today?

Ans. The Zydus Lifesciences share price was Rs 1,215.30 at 10:22 AM on 29 September 2026, up marginally from Rs 1,215.00, after touching a 52-week high of Rs 1,232.10.

What did the Zydus Lifesciences USFDA inspection at SEZ II Ahmedabad find?

Ans. The USFDA conducted a current good manufacturing practice inspection from 21 to 28 September 2026, which closed with one observation and no data-integrity issues.

Is this the same inspection as the New Jersey one reported earlier?

Ans. No. That inspection covered pharmacovigilance systems at an office from 22 to 25 September and ended with nil observations. This one covers manufacturing at a different site with a different outcome.

What does one observation with no data-integrity issue mean?

Ans. It means the inspector found a single point to address and did not flag concerns about the reliability of the company's data, which regulators treat as the more serious category.

Why is the Zydus Lifesciences share price near a 52-week high?

Ans. The stock has risen 45.4 percent from its 52-week low, helped by a string of clean or manageable inspection outcomes and strong momentum, though an RSI of 71.0 shows it is now overbought.

What are the key technical levels for the Zydus Lifesciences share price?

Ans. The key levels for the Zydus Lifesciences share price are SuperTrend support at Rs 1,141.36 and the 20-day average of Rs 1,153.05.

Is the Zydus Lifesciences share price expensive?

Ans. The P/E of 26.11 is below the industry figure of 38.42, so the stock trades at a discount to the sector despite the recent rally.

Should I buy Zydus Lifesciences shares after this inspection news?

Ans. The outcome is manageable, but the stock is technically overbought after a sharp run. Use a stop-loss and consult a SEBI-registered adviser before acting.